Novo Nordisk Wegovy pill study shows 4.1% weight loss after switching
A 194-patient real-world study presented at a diabetes meeting found patients who switched from injectable obesity drugs to oral semaglutide lost an average 4.1% of body weight in three months. Novo said the data support the Wegovy pill as it competes with Eli Lilly in oral obesity treatments.
Story updates
09:51:43 AM UTC
SquawkNews
Novo Nordisk disclosed real-world OCTANE study results already presented at EASD 2026 on Sept. 30 in Milan. Patients switching from injectable GLP-1 weight-loss drugs to once-daily Wegovy pill continued to lose weight over three months. The analysis also showed a meaningful share moved below the clinical obesity threshold, supporting the pill as an alternative for some users. Wegovy pill has launched in the US, UAE, UK, Germany, with additional market launches planned in coming quarters. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein. (C)